Genmab A/S (GMAB) Cash Flow Statement

The OCF/NI ratio of 0.17 in 2026Q2 suggests that reported net income of $303M was not matched by cash generation, with a $267M working capital outflow absorbing the difference. This pattern, where cash conversion is erratic and often below 1.0, implies that accrual-based earnings are not a reliable proxy for cash generation in the current period. Investors should monitor whether the working capital drag reflects delayed collections from partners or a structural shift toward product sales with longer cash cycles.

The FCF margin contracted from 35.8% in 2024Q3 to 4.2% in 2026Q2, indicating that the company's cash generation has reverted to a level more consistent with its underlying royalty and product sales, excluding one-time milestone payments. This trajectory suggests that the market should re-base expectations for FCF to the $200-300M quarterly range seen in 2025Q1 and 2025Q4, rather than the spike quarters. The gap between net income and FCF in 2026Q2, where net income was $303M but FCF was only $48M, highlights the impact of working capital and non-cash items on cash flow.

CapEx/Revenue ratios have stayed below 1.2% in most quarters, with the exception of 2025Q1 at 11.4%, which appears to be an anomaly. This suggests that the company does not require significant fixed asset investment to generate revenue, consistent with a royalty-heavy business model. However, as Genmab transitions to independent commercialization, investors should watch for potential increases in CapEx related to manufacturing or commercial infrastructure, which could pressure FCF margins.

The large negative working capital changes in 2026Q2 (-$267M) and 2024Q3 (-$524M) suggest that the company is experiencing substantial outflows related to receivables or contract assets, possibly due to the timing of partner payments. Conversely, the positive swing in 2025Q4 (+$253M) indicates a collection of receivables or deferred revenue recognition. This volatility implies that quarterly OCF figures are not indicative of underlying cash generation and should be analyzed on a trailing twelve-month basis to smooth out timing effects.

The company has historically paid no dividends, but has increasingly used cash for buybacks and M&A, with the $7.2B acquisition in 2025Q4 being a major deployment. This suggests a strategic pivot toward investing in pipeline assets or technologies, which may be necessary to offset the expected decline in Darzalex royalties. However, the large acquisition outflow in 2025Q4 was not matched by operating cash flow in that quarter, indicating reliance on existing cash reserves. Investors should monitor the return on these investments, as the balance sheet signal remains adequate but could become strained if acquisitions do not generate expected cash flows.

The cumulative gap of $2.7B between net income and operating cash flow suggests that a significant portion of reported earnings has not yet been converted to cash, possibly due to large receivables from partners or deferred revenue. This divergence warrants close attention, as it may indicate that the quality of earnings is lower than headline numbers suggest. However, the gap could also be explained by the timing of milestone payments, which are recognized as revenue but collected over time. Investors should monitor the aging of receivables and the sustainability of this gap, as a reversal could lead to a future cash flow surge.